World's Best Scientists 2026 revealed!
Atsushi Ohtsu

Atsushi Ohtsu

D-Index & Metrics

Medicine

D-Index
103
Citations
52531
World Ranking
7221
National Ranking
171

Overview

Atsushi Ohtsu is affiliated with Juntendo University in Japan and has a significant body of research primarily focused on medicine, with extensive contributions in oncology. Their work spans multiple subfields including oncology, pulmonary and respiratory medicine, cancer research, pathology and forensic medicine, and surgery.

The scientist's research topics cover a range of areas related to cancer, notably colorectal and gastric cancers. Key topics include colorectal cancer treatments and studies, gastric cancer management and outcomes, genetic factors in colorectal cancer, cancer genomics and diagnostics, cancer immunotherapy and biomarkers, esophageal cancer research and treatment, and cancer treatment and pharmacology.

Ohtsu has published research in numerous academic journals. The most frequent venues for their publications are the Journal of Clinical Oncology, Annals of Oncology, ESMO Open, Cancer Science, and Nature Medicine.

Some of the recent papers associated with Ohtsu include:

  • Clinical utility of circulating tumor DNA sequencing in advanced gastrointestinal cancer: SCRUM-Japan GI-SCREEN and GOZILA studies, 2020, Nature Medicine
  • Circulating tumor DNA-guided treatment with pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer: a phase 2 trial, 2021, Nature Medicine
  • Pembrolizumab versus paclitaxel for previously treated PD-L1-positive advanced gastric or gastroesophageal junction cancer: 2-year update of the randomized phase 3 KEYNOTE-061 trial, 2021, Gastric Cancer
  • Therapeutic landscape and future direction of metastatic colorectal cancer, 2023, Nature Reviews Gastroenterology & Hepatology
  • Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis treatment and follow-up of patients with localised colon cancer, 2021, Annals of Oncology

Ohtsu frequently collaborates with other researchers in the oncology field. Notable co-authors include Takayuki Yoshino, Hideaki Bando, Tomohiro Nishina, Kei Muro, and Hiroya Taniguchi.

Best Publications

  • Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial

    Yung Jue Bang;Eric Van Cutsem;Andrea Feyereislova;Hyun C. Chung

  • Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial

    Hansjochen Wilke;Kei Muro;Eric Van Cutsem;Sang Cheul Oh

  • Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer: Phase 2 Clinical KEYNOTE-059 Trial

    Charles S. Fuchs;Toshihiko Doi;Raymond W. Jang;Raymond W. Jang;Kei Muro

  • Randomized Trial of TAS-102 for Refractory Metastatic Colorectal Cancer

    Robert J Mayer;Eric Van Cutsem;Alfredo Falcone;Takayuki Yoshino

  • Bevacizumab in Combination With Chemotherapy As First-Line Therapy in Advanced Gastric Cancer: A Randomized, Double-Blind, Placebo-Controlled Phase III Study

    Atsushi Ohtsu;Manish A. Shah;Eric Van Cutsem;Sun Young Rha

  • Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial

    Kohei Shitara;Mustafa Özgüroğlu;Yung-Jue Bang;Maria Di Bartolomeo

  • Late phase II study of novel oral fluoropyrimidine anticancer drug S-1 (1 M tegafur–0.4 M gimestat–1 M otastat potassium) in advanced gastric cancer patients

    Y Sakata;A Ohtsu;N Horikoshi;K Sugimachi

  • Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study.

    Narikazu Boku;Seiichiro Yamamoto;Haruhiko Fukuda;Kuniaki Shirao

  • Lapatinib plus paclitaxel versus paclitaxel alone in the second-line treatment of HER2-amplified advanced gastric cancer in Asian populations: TyTAN - A randomized, phase III study

    Taroh Satoh;Rui-Hua Xu;Hyun Cheol Chung;Guo-Ping Sun

  • Randomized Phase III Trial of Fluorouracil Alone Versus Fluorouracil Plus Cisplatin Versus Uracil and Tegafur Plus Mitomycin in Patients With Unresectable, Advanced Gastric Cancer: The Japan Clinical Oncology Group Study (JCOG9205)

    Atsushi Ohtsu;Yasuhiro Shimada;Kuniaki Shirao;Narikazu Boku

  • Bevacizumab in Combination With Chemotherapy As First-Line Therapy in Advanced Gastric Cancer: A Biomarker Evaluation From the AVAGAST Randomized Phase III Trial

    Eric Van Cutsem;Sanne de Haas;Yoon-Koo Kang;Atsushi Ohtsu

  • Everolimus for previously treated advanced gastric cancer: Results of the randomized, double-blind, phase III GRANITE-1 study

    Atsushi Ohtsu;Jaffer A. Ajani;Yu Xian Bai;Yung Jue Bang

  • Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2/3 study

    Peter C. Thuss-Patience;Manish A. Shah;Atsushi Ohtsu;Eric Van Cutsem

  • Definitive Chemoradiotherapy for T4 and/or M1 Lymph Node Squamous Cell Carcinoma of the Esophagus

    Atsushi Ohtsu;Narikazu Boku;Kei Muro;Keisho Chin

  • Long-Term Toxicity After Definitive Chemoradiotherapy for Squamous Cell Carcinoma of the Thoracic Esophagus

    Satoshi Ishikura;Keiji Nihei;Atsushi Ohtsu;Narikazu Boku

  • Pertuzumab plus trastuzumab and chemotherapy for HER2-positive metastatic gastric or gastro-oesophageal junction cancer (JACOB): final analysis of a double-blind, randomised, placebo-controlled phase 3 study.

    Josep Tabernero;Paulo M. Hoff;Lin Shen;Atsushi Ohtsu

  • Nivolumab treatment for oesophageal squamous-cell carcinoma: an open-label, multicentre, phase 2 trial

    Toshihiro Kudo;Yasuo Hamamoto;Ken Kato;Takashi Ura

  • TAS-102 monotherapy for pretreated metastatic colorectal cancer: a double-blind, randomised, placebo-controlled phase 2 trial

    Takayuki Yoshino;Nobuyuki Mizunuma;Kentaro Yamazaki;Tomohiro Nishina

  • Phase II Study of a Combination of Irinotecan and Cisplatin Against Metastatic Gastric Cancer

    Narikazu Boku;Atsushi Ohtsu;Yasuhiro Shimada;Kuniaki Shirao

  • Bevacizumab in Combination With Chemotherapy as First-LineTherapyinAdvancedGastricCancer:ABiomarker EvaluationFromtheAVAGASTRandomizedPhaseIIITrial

    Eric Van Cutsem;Sanne de Haas;Yoon-Koo Kang;Atsushi Ohtsu

Frequent Co-Authors

Takayuki Yoshino
Takayuki Yoshino University of Tsukuba
Toshihiko Doi
Toshihiko Doi Okayama University
Narikazu Boku
Narikazu Boku St. Marianna University School of Medicine
Kei Muro
Kei Muro National Cancer Research Institute, UK
Kohei Shitara
Kohei Shitara Yahoo (United Kingdom)
Atsushi Ochiai
Atsushi Ochiai University of Tokyo
Teruhiko Yoshida
Teruhiko Yoshida National Cancer Research Institute, UK
Jun-ichi Sawada
Jun-ichi Sawada University of Shizuoka
Nagahiro Saijo
Nagahiro Saijo AstraZeneca (United Kingdom)

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring Medicine in the USA opens doors to numerous health-related careers beyond the traditional MD. For those interested in healthcare management, pursuing one of the cheapest mha programs online can provide a fast track to administration roles. Such programs are ideal for students seeking leadership positions in hospitals and medical organizations.

Nurses aiming to advance may consider one of the most affordable online dnp programs. Achieving a Doctorate in Nursing Practice enables higher clinical or executive opportunities while maintaining flexibility for working professionals.

For those drawn to pharmaceuticals, enrolling in an online pharmd program can lead to careers as licensed pharmacists. Many programs offer online coursework, allowing students to balance study with personal commitments.

Additionally, demand is growing in digital health information. Accredited online schools for health information management are equipping students for essential roles in medical data, privacy, and IT infrastructure.

Each of these online pathways offers flexibility and can complement or offer alternatives to traditional medical education. Explore which option aligns with your career goals and lifestyle.

Best Scientists Citing Atsushi Ohtsu

Trending Scientists

Recently Published Articles